Study details
Enrolling now
Combination Probiotic Trial
The University of Texas Health Science Center, Houston
NCT IDNCT03514784ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
70
Study length
about 9.6 years
Ages
4–16
Locations
1 site in TX
About this study
This trial is testing a combination probiotic (BB-12 with LGG) at different doses in children with autism spectrum disorder and gastrointestinal symptoms. The goal is to see if the probiotic is safe and well-tolerated, as well as how it affects behaviors, GI symptoms, and biomarkers related to inflammation, gut bacteria, and metabolites.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BB-12 with LGG (Higher Dose)
- 2.Take BB-12 with LGG (Lower Dose)
- 3.Take Placebo
PhasePhase 1/Phase 2
Primary goalEffects of BB-12+LGG at different doses on adverse events (safety)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low13%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Effects of BB-12+LGG at different doses on adverse events (safety)
Body systems
Psychiatry / Mental Health